Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 19, Issue 4, 2001, Pages 1167-1175

  Eskens, F A L M ^a   Awada, A ^a   Cutler, D L ^a   De Jonge, M J A ^a   Luyten, G P M ^a   Faber, M N ^a   Statkevich, P ^a   Sparreboom, A ^a   Verweij, J ^a   Hanauske, A R ^a   Piccart, M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LONAFARNIB; PROTEIN FARNESYLTRANSFERASE INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MALE; NEUROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STEADY STATE; VOMITING;

EID: 0035865305     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.4.1167     Document Type: Article

References (32)

1. Ras C-terminal processing enzymes: New drug targets?
2. Function and regulation of Ras
3. The Ras signal transduction pathway
4. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic
5. Farnesyltransferase inhibitors and anti Ras therapy
6. 2X-competitive inhibitors of farnesyltransferase as anti-cancer agents
7. The potential of farnesyltransferase inhibitors as cancer chemotherapeutics
8. Ras protein farnesyl transferase: A strategic target for anticancer therapeutic development
9. Farnesyl transferase inhibitors: Targeting the molecular basis of cancer
10. Ras oncogenes in human cancer: A review
11. Targeting farnesyltransferase: Is Ras relevant?
12. SCH 66336, an orally bioavailable tricyclic farnesyl protein transferase inhibitor, demonstrates broad and potent in-vivo antitumor activity
13. Activity of a farnesyl transferase inhibitor (SCH 66336) against a broad range of tumors taken directly from patients
14. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase in human tumor xenograft models and wap-ras transgenic mice
15. High-performance liquid chromatographic analysis of the antitumor agent SCH 66336 in cynomolgus monkey plasma and evaluation of its chiral inversion in animals
16. Noncompartmental analysis based on statistical moment theory
17. A phase I trial of the farnesyl protein transferase (FPT) inhibitor SCH 66336: Evidence for biological and clinical activity
18. Phase I and pharmacokinetic study of SCH 66336, a novel FPTI, using a 2-week on, 2-week off schedule
19. A clinical, pharmacodynamic and pharmacokinetic phase I study of SCH 66336 (SCH), an oral inhibitor of the enzyme farnesyl transferase, given once daily in patients with solid tumors
20. The farnesyl protein transferase (FPTase) inhibitor L-778,123 in patients with solid cancers
21. Phase I trial of the farnesyl protein transferase inhibitor L-778,123 on a 14 or 28-day schedule
22. Phase I and pharmacologic study with the novel farnesyl transferase inhibitor (FTI) R115777
23. Phase I clinical and pharmacokinetic trial of the farnesyl transferase inhibitor R115777 on a 21-day dosing schedule
24. Phase I and pharmacokinetic study of farnesyl transferase inhibitor R 115777 in advanced cancer
25. Phase I clinical trial of the farnesyltransferase (FT) inhibitor BMS-214662 in patients with advanced solid tumors
26. Pharmacokinetics of a potent orally bioavailable inhibitor of farnesyl protein transferase in the mouse, rat and cynomolgus monkey
27. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colonyrotating units
28. Dose-dependent pharmacokinetics: Experimental observations and theoretical considerations
29. Verapamil kinetics in normal subjects and patients with coronary artery spasm
30. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients
31. Paclitaxel pharmacokinetics and pharmacodynamics